Literature DB >> 8943945

Compensatory mechanisms associated with the hyperdynamic function of phospholamban-deficient mouse hearts.

G Chu1, W Luo, J P Slack, C Tilgmann, W E Sweet, M Spindler, K W Saupe, G P Boivin, C S Moravec, M A Matlib, I L Grupp, J S Ingwall, E G Kranias.   

Abstract

Phospholamban ablation is associated with significant increases in the sarcoplasmic reticulum Ca(2+)-ATPase activity and the basal cardiac contractile parameters. To determine whether the observed phenotype is due to loss of phospholamban alone or to accompanying compensatory mechanisms, hearts from phospholamban-deficient and age-matched wild-type mice were characterized in parallel. There were no morphological alterations detected at the light microscope level. Assessment of the protein levels of the cardiac sarcoplasmic reticulum Ca(2+)-ATPase, calsequestrin, myosin, actin, troponin I, and troponin T revealed no significant differences between phospholamban-deficient and wild-type hearts. However, the ryanodine receptor protein levels were significantly decreased (25%) upon ablation of phospholamban, probably in an attempt to regulate the release of Ca2+ from the sarcoplasmic reticulum, which had a significantly higher diastolic Ca2+ content in phospholamban-deficient compared with wild-type hearts (16.0 +/- 2.2 versus 8.6 +/- 1.0 mmol Ca2+/kg dry wt, respectively). The increases in Ca2+ content were specific to junctional sarcoplasmic reticulum stores, as there were no alterations in the Ca2+ content of the mitochondria or A band. Assessment of ATP levels revealed no alterations, although oxygen consumption increased (1.6-fold) to meet the increased ATP utilization in the hyperdynamic phospholamban-deficient hearts. The increases in oxygen consumption were associated with increases (2.2-fold) in the active fraction of the mitochondrial pyruvate dehydrogenase, suggesting increased tricarboxylic acid cycle turnover and ATP synthesis. 31P nuclear magnetic resonance studies demonstrated decreases in phosphocreatine levels and increases in ADP and AMP levels in phospholamban-deficient compared with wild-type hearts. However, the creatine kinase activity and the creatine kinase reaction velocity were not different between phospholamban-deficient and wild-type hearts. These findings indicate that ablation of phospholamban is associated with downregulation of the ryanodine receptor to compensate for the increased Ca2+ content in the sarcoplasmic reticulum store and metabolic adaptations to establish a new energetic steady state to meet the increased ATP demand in the hyperdynamic phospholamban-deficient hearts.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8943945     DOI: 10.1161/01.res.79.6.1064

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  22 in total

1.  Compromised myocardial energetics in hypertrophied mouse hearts diminish the beneficial effect of overexpressing SERCA2a.

Authors:  Ilka Pinz; Rong Tian; Darrell Belke; Eric Swanson; Wolfgang Dillmann; Joanne S Ingwall
Journal:  J Biol Chem       Date:  2011-01-29       Impact factor: 5.157

2.  In vivo gene delivery of XIAP protects against myocardial apoptosis and infarction following ischemia/reperfusion in conscious rabbits.

Authors:  Song-Jung Kim; Alex Kuklov; George J Crystal
Journal:  Life Sci       Date:  2011-01-25       Impact factor: 5.037

3.  Phospholemman is a negative feed-forward regulator of Ca2+ in β-adrenergic signaling, accelerating β-adrenergic inotropy.

Authors:  Jason H Yang; Jeffrey J Saucerman
Journal:  J Mol Cell Cardiol       Date:  2012-01-20       Impact factor: 5.000

Review 4.  MR spectroscopy of transgenic mice.

Authors:  M Spindler; K W Saupe; J S Ingwall
Journal:  MAGMA       Date:  1998-09       Impact factor: 2.310

5.  Modulation of ventricular function through gene transfer in vivo.

Authors:  R J Hajjar; U Schmidt; T Matsui; J L Guerrero; K H Lee; J K Gwathmey; G W Dec; M J Semigran; A Rosenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

6.  A compartmentalized mathematical model of the β1-adrenergic signaling system in mouse ventricular myocytes.

Authors:  Vladimir E Bondarenko
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

7.  Phospholamban regulates nuclear Ca2+ stores and inositol 1,4,5-trisphosphate mediated nuclear Ca2+ cycling in cardiomyocytes.

Authors:  Mu Chen; Dongzhu Xu; Adonis Z Wu; Evangelia Kranias; Shien-Fong Lin; Peng-Sheng Chen; Zhenhui Chen
Journal:  J Mol Cell Cardiol       Date:  2018-09-24       Impact factor: 5.000

8.  Functional and transcriptomic insights into pathogenesis of R9C phospholamban mutation using human induced pluripotent stem cell-derived cardiomyocytes.

Authors:  Delaine K Ceholski; Irene C Turnbull; Chi-Wing Kong; Simon Koplev; Joshua Mayourian; Przemek A Gorski; Francesca Stillitano; Angelos A Skodras; Mathieu Nonnenmacher; Ninette Cohen; Johan L M Björkegren; Daniel R Stroik; Razvan L Cornea; David D Thomas; Ronald A Li; Kevin D Costa; Roger J Hajjar
Journal:  J Mol Cell Cardiol       Date:  2018-05-09       Impact factor: 5.000

9.  Early beneficial effects of bone marrow-derived mesenchymal stem cells overexpressing Akt on cardiac metabolism after myocardial infarction.

Authors:  Massimiliano Gnecchi; Huamei He; Luis G Melo; Nicolas Noiseaux; Fulvio Morello; Rudolf A de Boer; Lunan Zhang; Richard E Pratt; Victor J Dzau; Joanne S Ingwall
Journal:  Stem Cells       Date:  2009-04       Impact factor: 6.277

10.  Regulation of excitation-contraction coupling in mouse cardiac myocytes: integrative analysis with mathematical modelling.

Authors:  Jussi T Koivumäki; Topi Korhonen; Jouni Takalo; Matti Weckström; Pasi Tavi
Journal:  BMC Physiol       Date:  2009-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.